Around 70% of cancer deaths come from cancers with no routine screening programme. The NHS-Galleri trial - 142,000 participants, the largest randomised trial of multi-cancer early detection ever conducted - recently reported its results. The headlines said it failed.

This video walks through the screening architecture we already have, the technology behind multi-cancer blood testing, what the trial actually found, and why the honest clinical position is more nuanced than any headline can accommodate.

Topics covered:
– Mammography, cervical screening, colonoscopy, PSA — established trade-offs
– Cell-free DNA methylation and tissue-of-origin prediction
– Sensitivity by stage: what 51.5% overall and 17–20% Stage I actually mean
– False positives vs false negatives — and which is more dangerous
– Lead-time bias and length bias in screening
– The NHS-Galleri primary endpoint, why it was not met, and what the secondary findings suggest
– Population-level guidelines vs individual-level decisions

Studies on GRAIL Galleri test referenced in this video:

1. CCGA Clinical Validation (test performance: sensitivity, specificity, stage breakdown)
Klein EA et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Annals of Oncology. 2021;32(9):1167–1177.
https://www.annalsofoncology.org/article/s0923-7534(21)02046-9/fulltext

2. PATHFINDER (real-world diagnostic pathway after a positive result)
Schrag D, Beer TM, McDonnell CH et al. Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study. Lancet. 2023;402(10409):1251–1260.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01700-2/abstract

3. NHS-Galleri (142,000-participant population-scale RCT — press release only; full data expected ASCO late May/early June 2026)
GRAIL press release, 19 February 2026.
https://grail.com/press-releases/landmark-nhs-galleri-trial-demonstrates-a-substantial-reduction-in-stage-iv-cancer-diagnoses-increased-stage-i-and-ii-detection-of-deadly-cancers-and-four-fold-higher-cancer-detection-rate/

Dmitry Sokolov MD
Consultant Anaesthetist | Lifestyle Medicine Physician
dmitrysokolovmd.com